Close Menu

BMS

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – GNS Healthcare today announced a deal to use clinical and molecular information from Bristol-Myers Squibb aimed at immuno-inflammation.

Advanced sequencing technologies are great for discovery, but not ready to be incorporated into Qiagen's commercial companion diagnostics portfolio, according to CEO Peer Schatz.

The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The study, led by researchers at OHSU, also identified a series of proteins linked to the Src signaling pathway that could prove useful in identifying renal cell carcinoma patients most likely to respond to treatment with Src inhibitors.

The company claims Agilent, 454 Life Sciences, Navigenics, Pfizer, and others are infringing on its patent covering a method for analyzing non-coding DNA sequences.

Bristol-Myers Squibb will now evaluate Tekmira's new lipid nanoparticles for the delivery of siRNA to tumors and tissues outside of the liver.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.